Sign In
Buy GRTX
$0.100
-0.0010 (-0.99%)
At Close: Jun 03, 2026
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
07:36am, Wednesday, 06'th Sep 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
01:19pm, Friday, 18'th Aug 2023
Galera Therapeutics, Inc. (GRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
08:39am, Monday, 14'th Aug 2023
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
07:00am, Monday, 14'th Aug 2023
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect
01:04pm, Thursday, 10'th Aug 2023
Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investigational therapeutic avasopasem manganese (avasopas
Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?
08:43am, Thursday, 10'th Aug 2023
Galera Therapeutics (NASDAQ: GRTX ) stock is falling hard on Thursday following a drug rejection by the FDA! In a Complete Response Letter ( CRL ), the FDA rejected the company's New Drug Application
Galera shares tank after US FDA declines to approve inflammation disease drug
07:00pm, Wednesday, 09'th Aug 2023
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing st
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
04:31pm, Wednesday, 09'th Aug 2023
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients
06:33pm, Monday, 24'th Apr 2023
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients.
Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation
10:24pm, Tuesday, 21'st Feb 2023
On February 21, 2023, Piper Sandler initiated coverage of Galera Therapeutics with a Overweight recommendation.
Galera to Present at Piper Sandler Annual Healthcare Conference
07:00am, Tuesday, 22'nd Nov 2022
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
07:00am, Monday, 26'th Sep 2022
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Tuesday, 06'th Sep 2022
MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation
12:09pm, Wednesday, 29'th Jun 2022
Galera Therapeutics Inc (NASDAQ: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non
